News
CeleCor completes submission of FDA New Drug Application for investigational heart-attack drug
June 24, 2026
DEL MAR, CALIF., USA – CeleCor Therapeutics has submitted the final section of its New Drug Application for the company’s investigational heart-attack drug, zalunfiban (DisaggproTM), to the US Food and Drug Administration.
Read more Rapid zalunfiban treatment at 1st point of medical contact lowered risk of more severe heart damage in combination with other serious heart-attack complications
November 10, 2025
DEL MAR, CALIF., USA – Rapid treatment with CeleCor Therapeutics’ investigational heart-attack drug, zalunfiban, resulted in higher levels of blood flow to the heart and an approximately 21% reduction in a patient’s risk of experiencing a larger MI or one complicated by death, stroke, reinfarction, stent thrombosis or heart failure, new Phase 3 data show.
Read more Phase 3 Study of Novel Anti-Platelet Drug for Heart Attack Reports Positive Topline Results
September 23, 2025
DEL MAR, CALIF., USA – CeleCor Therapeutics’ multinational Phase 3 clinical trial of its investigational heart-attack drug DisaggproTM (zalunfiban) has shown positive primary efficacy and primary safety outcomes.
Read more Celecor Completes Multinational Phase 3 Registrational Study of Novel Anti-Platelet Agent for Heart Attack
May 27, 2025
CeleCor Therapeutics has completed its multinational Phase 3 clinical trial of DisaggproTM (zalunfiban), an investigational heart-attack drug designed for rapid use at first point of medical contact – including before patients reach the hospital.
Read moreFor additional updates including the latest CeleCor news, check out our LinkedIn page.
